Bibliography
- Merlini PA, Rossi M, Menozzi A, Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004;109(18):2203-6
- Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011;364(18):1746-60
- Andreotti F, Testa L, Biondi-Zoccai GG, Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006;27(5):519-26
- Rothberg MB, Celestin C, Fiore LD, Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005;143(4):241-50
- Rose AJ, Hylek EM, Ozonoff A, Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes 2011;4(1):22-9
- Wallentin L, Yusuf S, Ezekowitz MD, Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376(9745):975-83
- White HD. Targeting therapy to the fibrin-mediated pathophysiology of acute coronary syndrome. Clin Appl Thromb Hemost 2012; [Epub ahead of print]
- Weitz JI. New oral anticoagulants: a view from the laboratory. Am J Hematol 2012;87(Suppl 1):S133-S6
- Wallentin L, Wilcox RG, Weaver WD, Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362(9386):789-97
- De Caterina R, Husted S, Wallentin L, New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on thrombosis-task force on anticoagulants in heart disease position paper. J Am Coll Cardiol 2012;59(16):1413-25
- Granger CB, Alexander JH, McMurray JJ, Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981-92
- Patel MR, Mahaffey KW, Garg J, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91
- Ruff CT, Giugliano RP, Antman EM, Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160(4):635-41
- Mega JL, Braunwald E, Wiviott SD, Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366(1):9-19
- Alexander JH, Lopes RD, James S, Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365(8):699-708
- Hamm CW, Bassand JP, Agewall S, ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32(23):2999-3054
- Bhatt DL, Eagle KA, Ohman EM, Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010;304(12):1350-7
- Mega JL, Hochholzer W, Frelinger AL III, Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011;306(20):2221-8
- Wallentin L, Becker RC, Budaj A, Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361(11):1045-57
- Montalescot G, Wiviott SD, Braunwald E, Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373(9665):723-31
- Janssen Pharmaceuticals, Inc. Xarelto® (rivaroxaban) Prescribing Information. 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202439s001lbl.pdf [Accessed 20 November 2012]
- Bayer HealthCare. Xarelto®. Summary of product characteristics – EU. 2012. Available from: http://www.xarelto.com/html/downloads/Xarelto-Prescribing_Information-May-2012.pdf [Accessed 15 February 2013]
- Xu XS, Moore K, Burton P, Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. Br J Clin Pharmacol 2012;74(1):86-97
- Mega J, Braunwald E, Mohanavelu S, Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374:29-38
- Eikelboom JW, Mehta SR, Anand SS, Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006;114(8):774-82
- Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 1985;53:363-73
- Wang TY, Xiao L, Alexander KP, Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. Circulation 2008;118(21):2139-45
- Armstrong PW, Harrington RA. Road mapping ATLAS ACS 2: are we there yet? Eur Heart J 2012;33(20):2510-12
- Turpie AG, Kreutz R, Llau J, Management consensus guidance for the use of rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2012;108(5):876-86
- Eerenberg ES, Kamphuisen PW, Sijpkens MK, Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124(14):1573-9
- US Food and Drug Administration. FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm. 2011. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htm [Accessed 15 February 2013]
- US Food and Drug Administration. FDA approves Xarelto to reduce risk of blood clots after hip, knee replacements. 2011. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm261839.htm [Accessed 15 February 2013]
- US Food and Drug Administration. FDA expands use of Xarelto to treat, reduce recurrence of blood clots. 2012. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm [Accessed 15 February 2013]
- European Medicines Agency: science Medicines Health. Xarelto: rivaroxaban. Summary od opinion (post authorisation). 2011. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000944/WC500112784.pdf [Accessed 15 February 2013]
- Janssen Pharmaceuticals, Inc. PR Newswire: FDA Advisory Committee recommends against approval of oral anticoagulant XARELTO® to reduce the risk of secondary cardiovascular events in patients with acute coronary syndrome. 2012. Available from: http://www.prnewswire.com/news-releases/fda-advisory-committee-recommends-against-approval-of-oral-anticoagulant-xarelto-to-reduce-the-risk-of-secondary-cardiovascular-events-in-patients-with-acute-coronary-syndrome-153247295.html [Accessed 15 February 2013]
- Komocsi A, Vorobcsuk A, Kehl D, Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2012;172(20):1537-45
- Hernandez AV. No place for novel oral anticoagulants in current treatment of acute coronary syndromes: comment on "Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome". Arch Intern Med 2012;172(20):1546-7
- Stone GW, Maehara A, Lansky AJ, A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011;364(3):226-35
- Masso Gonzalez EL, Patrignani P, Tacconelli S, Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010;62(6):1592-601
- Mehran R, Rao SV, Bhatt DL, Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium (BARC). Circulation 2011;123(23):2736-47